February 10, 2003
Pain & Central Nervous System Week
According to recent research from the United States, "Enhancing myelin repair remains an important therapeutic goal in primary demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis (MS)," wrote M.M.P. Soldan and coauthors, Mayo Clinic, Department of Immunology.
"The emerging heterogeneity of pathology within MS lesions, and differential oligodendrocyte survival in particular, suggests that therapeutic strategies may need to be tailored to an individual patient's requirements. "
The researchers concluded: "A number of therapeutic strategies have been proposed to enhance myelin repair in the CNS: cell transplantation, growth factor therapy, and antibody therapy, but each proposed therapy has different implications with respect to pathogenetic mechanisms of demyelination. Of these, antibody therapy is the most amenable to immediate application in patients, but a combination of therapeutic approaches may be required in practice."
Soldan and colleagues published their study in the Journal of Infectious Diseases (Heterogeneity of pathogenesis in multiple sclerosis: Implications for promotion of remyelination. J Infec Dis, 2002;186(Suppl. 2):S248-S253).
For additional information, contact M. Rodriguez, Mayo Clinic, Dept. of Immunology, 200 1st St. SW, Rochester, MN 55905, USA.
To subscribe to the Journal of Infectious Diseases, contact the publisher: University of Chicago Press, 1427 E 60TH St., Chicago, IL 60637-2954, USA.
The information in this article comes under the major subject areas of Neurology and CNS.
This article was prepared by Pain & Central Nervous System
Week editors from staff and other reports.
© Copyright 2003 Pain & Central Nervous System Week